GH Live signals | Maximize Profits with Getagraph.com

SELL 4656 min ago

@ $28.95

Issued: 28 Jun 2024 @ 14:19

Return: -2.37%

Previous signal: Jun 28 - 12:12

Previous signal: Buy

Return: -0.31 %

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.23% compare to its pairs and should correct upwards.

Stats
Today's Volume	1.12M
Average Volume	2.30M
Market Cap	3.46B
EPS	$-0.940 ( Q1 \| 2024-05-09 )
Next earnings date	( $-0.570 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.21 (Sector) 42.63 (Industry) 0
ATR14	$1.510 (5.34%)

ACRS 4.55%

AKU -17.87%

APDN 33.45%

BDSX 0.00%

BIOC 0.00%

BNGO -2.32%

BNR -0.16%

CDNA -0.97%

CEMI 0.22%

CHEK 3.03%

CNTG 2.73%

CSTL -2.66%

DMTK -11.32%

DRIO -1.68%

EXAS 0.43%

FLDM -7.02%

FLGT 2.14%

GENE -5.37%

GH -2.15%

GTH 0.12%

HTGM 0.00%

ICLR 0.97%

IDXX -2.22%

ILMN 1.07%

ISPC -1.91%

LAB -2.26%

LMDX 0.00%

MDXH -1.26%

ME -3.83%

MEDP -1.12%

MYGN -2.00%

MYNZ -13.92%

NDRA -4.43%

NEO 0.43%

NEOG -3.77%

NOTV -4.22%

NTRA -0.44%

OCDX 0.92%

OLK 0.27%

OPGN -2.98%

OPK -1.60%

PMD -2.89%

PRPO 6.01%

PSNL 2.14%

RDNT -0.63%

SERA 2.03%

SHC -2.44%

SQL 0.00%

STIM -2.78%

STRR -3.52%

STRRP -6.57%

SYNH 0.02%

TRIB 6.28%

TTOO 0.75%

TWST -0.71%

VIVO 0.00%

XGN -0.55%

Insider Trading

Date	Person	Action	Amount	type
2024-06-15	Tariq Musa	Sell	250	Restricted Stock Units
2024-06-15	Tariq Musa	Buy	250	Common Stock
2024-06-15	Saia John G.	Buy	4 017	Common Stock
2024-06-15	Saia John G.	Sell	1 434	Common Stock
2024-06-15	Saia John G.	Sell	4 017	Restricted Stock Units

INSIDER POWER
7.07
Last 100 transactions
Buy: 680 676 \| Sell: 595 067

Correlation (AI algo v.1.1b): Undervalued: 0.23% $28.33 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.84 (strong)

Short: 0.08 (neutral)

Signal:(75) Neutral

Guardant Health Inc Correlation

10 Most Positive Correlations
KOSS	0.94
MSEX	0.89
FTDR	0.879
JJSF	0.876
FLNC	0.87
ALHC	0.87
NECB	0.867
MYFW	0.866
BKSC	0.862
RNRG	0.855

10 Most Negative Correlations
ARQT	-0.863
ELEV	-0.831
HQY	-0.831
ALRN	-0.829
LTRPA	-0.823
FAAR	-0.819
USOI	-0.817
CFSB	-0.817
ASND	-0.816
JSPR	-0.816

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Guardant Health Inc Correlation - Currency/Commodity

-0.63
( weak negative )

-0.68
( moderate negative )

0.00
( neutral )

0.08
( neutral )

0.38
( neutral )

-0.29
( neutral )

Guardant Health Inc Financials

Annual	2023
Revenue:	$563.95M
Gross Profit:	$336.90M (59.74 %)
EPS:	$-4.28

FY	2023
Revenue:	$563.95M
Gross Profit:	$336.90M (59.74 %)
EPS:	$-4.28

FY	2022
Revenue:	$449.54M
Gross Profit:	$293.21M (65.23 %)
EPS:	$-6.41

FY	2021
Revenue:	$373.65M
Gross Profit:	$250.74M (67.11 %)
EPS:	$-4.00

Financial Reports:

No articles found.

Guardant Health Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.